Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isis Pharmaceuticals has initiated a Phase I study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides.
Subscribe to our email newsletter
ISIS-APOCIIIRx works by inhibiting the production of apolipoprotein C-III (apoC-III), a traditionally ‘undruggable’ target that plays an important role in the regulation of triglycerides.
Isis Cardiovascular Diseases Drug Discovery Research vice president Rosanne Crooke said many of the current therapies designed to lower triglycerides are associated with undesirable side effects, such as flushing.
"In preclinical studies, antisense inhibition of apoC-III reduced the target mRNA and protein, lowered triglyceride levels in plasma, mitigated symptoms of metabolic syndrome and decreased atherosclerosis," Crooke said.